Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Toripalimab by Shanghai Junshi Biosciences for Metastatic Biliary Tract Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Biliary Tract Cancer. According...
Toripalimab by Shanghai Junshi Biosciences for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Recurrent Head And Neck Squamous...
Toripalimab by Shanghai Junshi Biosciences for Synovial Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Synovial Sarcoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction....
Toripalimab by Shanghai Junshi Biosciences for Oropharyngeal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Oropharyngeal Cancer. According to GlobalData,...
Toripalimab by Coherus BioSciences for Solid Tumor: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
Toripalimab by Shanghai Junshi Biosciences for Hepatocellular Carcinoma: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Hepatocellular Carcinoma. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Gastric Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Gastric Cancer. According to GlobalData,...
Toripalimab by Coherus BioSciences for Melanoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase II for Melanoma. According to GlobalData, Phase II...
Toripalimab by Shanghai Junshi Biosciences for Metastatic Colorectal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Metastatic Colorectal Cancer. According to...
Toripalimab by Shanghai Junshi Biosciences for Cervical Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Cervical Cancer. According to GlobalData,...
Toripalimab by Coherus BioSciences for Soft Tissue Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
Toripalimab by Coherus BioSciences for Chondrosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Chondrosarcoma. According to GlobalData, Phase I...
Toripalimab by Shanghai Junshi Biosciences for Gallbladder Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Gallbladder Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Non-Small Cell Lung Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase III for Non-Small Cell Lung Cancer. According...
Toripalimab by Coherus BioSciences for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According...
Toripalimab by Shanghai Junshi Biosciences for Rectal Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Rectal Cancer. According to GlobalData,...
Toripalimab by Shanghai Junshi Biosciences for Ovarian Cancer: Likelihood of Approval
Toripalimab is under clinical development by Shanghai Junshi Biosciences and currently in Phase II for Ovarian Cancer. According to GlobalData,...
Toripalimab by Coherus BioSciences for Soft Tissue Sarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
Toripalimab by Coherus BioSciences for Chondrosarcoma: Likelihood of Approval
Toripalimab is under clinical development by Coherus BioSciences and currently in Phase I for Chondrosarcoma. According to GlobalData, Phase I...